Article By:
ChinaBio® Today
Saturday, March 6, 2021 12:34 PM EDT
OrbiMed Advisors announced it has secured $3.5 billion in commitments for its latest capital raise, including $800 million for OrbiMed Asia Partners IV. Connect Biopharma of Taicang has filed for a NASDAQ IPO that could raise $100 million.